Placebo (matched to SUZ)

DRUG5 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Acute PainDiabetic Peripheral Neuropathic PainDiabetic Peripheral Neuropathy

Phase 2

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

CompletedNCT05660538

Vertex Pharmaceuticals IncorporatedDiabetic Peripheral Neuropathy

Start: 2022-12-20End: 2023-10-25Updated: 2025-07-01

Phase 3

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

CompletedNCT05553366

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2022-10-03End: 2023-12-15Updated: 2025-08-01

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

CompletedNCT05558410

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2022-10-10End: 2023-09-11Updated: 2025-07-01

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

RecruitingNCT06628908

Vertex Pharmaceuticals IncorporatedDiabetic Peripheral Neuropathic Pain

Start: 2024-10-01End: 2027-05-31Target: 1100Updated: 2026-03-31

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

RecruitingNCT07231419

Vertex Pharmaceuticals IncorporatedDiabetic Peripheral Neuropathic Pain

Start: 2025-11-21End: 2027-04-06Target: 734Updated: 2026-04-01

Related Papers

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials

Anesthesiology2025-03-2128 citations